葛兰素集团在吸入性糖皮质激素治疗哮喘领域的专利布局分析

Analysis of Patents of GSK about Inhaled Corticosteroid in the Treatment of Asthma

目的由于葛兰素集团在吸入性糖皮质激素治疗哮喘领域的相关产品如辅舒酮和舒利迭在全球范围内取得到了较好的经济效益。因此,笔者对葛兰素集团在吸入性糖皮质激素(ICS)治疗哮喘方面的相关专利布局与市场情况进行分析。方法利用国家知识产权局自主开发的S系统,包括CNABS和DWPI数据库,针对葛兰素集团在ICS治疗哮喘领域的专利总体布局和重点产品专利进行了分析,主要研究了在制剂、装置和辅料方面的专利布局。结果辅舒酮和舒利迭制剂核心专利虽然已到期,但是葛兰素集团在呼吸给药的装置、辅料以及新产品等方面均有相关专利布局。结论预测未来几年内,葛兰素集团在该领域仍占据市场主导地位,我国医药创新主体在产品研发的同时应当重视专利保护,并且在专利布局方面应当向葛兰素集团学习。

OBJECTIVE Because of the good economic benefits of Flixotide and Seretide in the treatment of asthma, we analyzed the patents applications and market of GSK about inhaled corticosteroid in the treatment of asthma. METHODS By using S system of SIPO,including CNABS and DWPI database, the patents about the preparations, device and ingredient of the product had been discussed carefully. RESULTS The patents of preparations of Flixotide and Seretide had expired, however, GSK had already applied many patents cover the drug administration apparatus, ingredients and new products. CONCLUSION We forecast GSK will occupy the market dominant position for the near future years of this field. The domestic research institutions should pay attention to patent protection, and learn from GSK in the patent layout.